The NEJ009 study, the first phase III study to compared between EGFR TKI combined with chemotherapy and EGFR TKI monotherapy in advanced NSCLC, showed a significantly higher ORR (84% vs 67%), longer median PFS (20.9 months vs 11.9 months), and longer OS (50.9 months vs 38.8 months) in the combination group (34). This evidence concerns the gene EGFR and non-small cell lung carcinoma.